COMMUNIQUÉS West-GlobeNewswire

Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca

23/09/2024 - 13:25

1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCIC TORONTO, Sept. 23, 2024 (GLOBE [...]

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23/09/2024 - 13:13

Kayfanda ® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda based on data from [...]

Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare

23/09/2024 - 13:13

Kayfanda ® (odévixibat) a été approuvé comme nouvelle option thérapeutique pour le prurit cholestatique chez l’enfant de six mois ou plus atteint du syndrome d’Alagille, une maladie rare du foie. L’autorisation de mise [...]

Kraig Biocraft Laboratories Launches Spider Silk Production at Recently Completed Higher Capacity Facility

23/09/2024 - 13:05

ANN ARBOR, Mich., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), proudly announces the initiation of its first production cycle for the BAM-1 parental [...]

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

23/09/2024 - 13:05

LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

23/09/2024 - 13:01

Independent evaluation of KP.3.1.1 and LB.1 variants shows in vitro pseudovirus neutralization potency of PEMGARDA in-line with prior variants tested Proprietary, ongoing SARS-CoV-2 spike analyses demonstrate consistent [...]

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

23/09/2024 - 13:00

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

23/09/2024 - 13:00

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations [...]

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

23/09/2024 - 13:00

New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity [...]

Opthea Joins the S&P/ASX 300 Index

23/09/2024 - 13:00

MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

23/09/2024 - 13:00

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]

Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024)

23/09/2024 - 13:00

Presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL (sublingual cyclobenzaprine HCl) Composition and methods patents based on the eutectic formulation of TNX-102 [...]

Synergia Medical Successfully Implants First Patients With NAO.VNS™

23/09/2024 - 08:08

Brussels, 23 September 2024 – Synergia Medical, a leader in the development of optoelectronic medical devices, is pleased to announce the successful implantation of its groundbreaking NAO.VNS system in the first two [...]

Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatric Nephrology (ESPN) 2024

23/09/2024 - 08:00

“Totality-of-the-evidence”, including analytical, non-clinical and clinical data, supports extrapolation of atypical hemolytic uremic syndrome (aHUS) indication for EPYSQLI INCHEON, South Korea, Sept. 23, 2024 (GLOBE [...]

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

23/09/2024 - 07:30

Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone [...]

Nicox et Glaukos signent un accord exclusif de recherche incluant une option de licence mondiale pour NCX 1728

23/09/2024 - 07:30

Communiqué de presse Nicox et Glaukos signent un accord exclusif de recherche incluant une option de licence mondiale pour NCX 1728 L’option permettra à Glaukos de conclure des accords exclusifs de licence mondiale [...]

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

23/09/2024 - 07:30

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of [...]

GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine

23/09/2024 - 07:30

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 23 septembre 2024 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

23/09/2024 - 07:00

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients 1 TD is an involuntary movement [...]